Vilmar AC - Search Results

1

Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.

Vilmar AC, Santoni-Rugiu E, Sørensen JB. Vilmar AC, et al. Clin Cancer Res. 2011 Aug 1;17(15):5205-14. doi: 10.1158/1078-0432.CCR-11-0658. Epub 2011 Jun 20. Clin Cancer Res. 2011. PMID: 21690572 Clinical Trial.

2

RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.

Vilmar A, Garcia-Foncillas J, Huarriz M, Santoni-Rugiu E, Sorensen JB. Vilmar A, et al. Lung Cancer. 2012 Mar;75(3):306-12. doi: 10.1016/j.lungcan.2011.08.016. Epub 2011 Oct 13. Lung Cancer. 2012. PMID: 21996087 Clinical Trial.

3

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.

Vilmar AC, Santoni-Rugiu E, Sørensen JB. Vilmar AC, et al. Ann Oncol. 2010 Sep;21(9):1817-1824. doi: 10.1093/annonc/mdq053. Epub 2010 Mar 23. Ann Oncol. 2010. PMID: 20332140 Free article. Clinical Trial.

4

Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives.

Vilmar AC, Sorensen JB. Vilmar AC, et al. Eur Respir Rev. 2011 Mar;20(119):45-52. doi: 10.1183/09059180.00007310. Eur Respir Rev. 2011. PMID: 21357891 Free PMC article. Review.

5

Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.

Vilmar AC, Santoni-Rugiu E, Sorensen JB. Vilmar AC, et al. Ann Oncol. 2013 Feb;24(2):309-314. doi: 10.1093/annonc/mds335. Epub 2012 Oct 4. Ann Oncol. 2013. PMID: 23038758 Free article. Clinical Trial.

6

Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer.

Thomsen Lønborg J, Vilmar A, Mård D, Astrup Jensen S, Sørensen JB. Thomsen Lønborg J, et al. Oncol Rep. 2007 Oct;18(4):1023-9. Oncol Rep. 2007. PMID: 17786369

7

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Vilmar A, Sørensen JB. Vilmar A, et al. Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19. Lung Cancer. 2009. PMID: 18804893 Review.

8

ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.

Vilmar A, Santoni-Rugiu E, Sørensen JB. Vilmar A, et al. Eur J Cancer. 2010 Jun;46(9):1554-62. doi: 10.1016/j.ejca.2010.02.045. Epub 2010 Apr 13. Eur J Cancer. 2010. PMID: 20395129 Clinical Trial.

9

Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer.

Vilmar A, Santoni-Rugiu E, Cillas JG, Huarriz M, Sørensen JB. Vilmar A, et al. Anticancer Res. 2014 Jun;34(6):2991-6. Anticancer Res. 2014. PMID: 24922664 Clinical Trial.

10

Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.

Jensen SA, Vilmar A, Sørensen JB. Jensen SA, et al. Med Oncol. 2006;23(4):521-31. doi: 10.1385/mo:23:4:521. Med Oncol. 2006. PMID: 17303911

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters